N. John

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.

J. Lechner-Scott, M. Slee, F. Grand'Maison, 2024, Multiple sclerosis.

Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

J. Lechner-Scott, M. Slee, A. Ponsonby, 2023, Journal of neurology.

Predictors of Multiple Sclerosis Severity Score in Patients with Multiple Sclerosis

M. Wallin, T. Kahraman, R. Marrie, 2020 .